News

not found

WHO updates list of drug-resistant bacteria

The World Health Organization (WHO) today released its updated Bacterial Priority Pathogens List (BPPL) 2024, featuring 15 families of antibiotic-resistant bacteria grouped into critical, high and medium categories for prioritization. The list provides guidance on the development of new and necessary treatments to stop the spread of antimicrobial resistance (AMR). AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to medicines, making people sicker and increasing the risk of disease spread, illness and deaths. AMR is driven in large part by the misuse and overuse of antimicrobials. The updated BPPL incorporates new evidence and expert insights to guide research and development (R&D) for new antibiotics and promote international coordination to foster innovation. “Antimicrobial resistance jeopardizes our ability to effectively treat high burden infections, such as tuberculosis, leading to severe illness and increased mortality rates," said Dr Jérôme Salomon, WHO's Assistant Director-General for Universal Health Coverage, Communicable and Noncommunicable Diseases. The WHO BPPL 2024 includes the following bacteria: Critical priority: Acinetobacter baumannii, carbapenem-resistant; Enterobacterales, third-generation cephalosporin-resistant; and  Enterobacterales, carbapenem-resistant; Mycobacterium tuberculosis, rifampicin-resistant (included after an independent analysis with parallel tailored criteria, and subsequent application of an adapted multi-criteria decision analysis matrix).    High priority: Salmonella Typhi, fluoroquinolone-resistant Shigella spp., fluoroquinolone-resistant Enterococcus faecium, vancomycin-resistant Pseudomonas aeruginosa, carbapenem-resistant Non-typhoidal Salmonella, fluoroquinolone-resistant Neisseria gonorrhoeae, third-generation cephalosporin- and/or fluoroquinolone-resistant Staphylococcus aureus, methicillin-resistant Medium priority:  Group A streptococci, macrolide-resistant Streptococcus pneumoniae, macrolide-resistant Haemophilus influenzae, ampicillin-resistant Group B streptococci, penicillin-resistant

  • 20 May, 10:00
  • Read more
not found

AstraZeneca withdrawing Covid vaccine worldwide

The Oxford-AstraZeneca Covid vaccine is being withdrawn worldwide, months after the pharmaceutical giant admitted for the first time in court documents that it can cause a rare and dangerous side effect. The vaccine can no longer be used in the European Union after the company voluntarily withdrew its “marketing authorisation”. The application to withdraw the vaccine was made on March 5 and came into effect on Tuesday. Similar applications will be made in the coming months in the UK and in other countries that had approved the vaccine, known as Vaxzevria. The decision to withdraw it brings to an end the use of the jab, which was heralded by Boris Johnson as a “triumph for British science” and credited with saving more than six million lives. AstraZeneca said the vaccine was being removed from markets for commercial reasons. It said the vaccine was no longer being manufactured or supplied, having been superseded by updated vaccines that tackle new variants.  Vaxzevria has come under intense scrutiny in recent months over a very rare side effect, which causes blood clots and low blood platelet counts. AstraZeneca admitted in court documents lodged with the High Court in February that the vaccine “can, in very rare cases, cause TTS”. TTS – which stands for Thrombosis with Thrombocytopenia Syndrome – has been linked to at least 81 deaths in the UK as well as hundreds of serious injuries. AstraZeneca is being sued by more than 50 alleged victims and grieving relatives in a High Court case. But AstraZeneca has insisted the decision to withdraw the vaccine is not linked to the court case or its admission that it can cause TTS. It said the timing was pure coincidence.

  • 10 May, 09:00
  • Read more
not found

New asthma cause identified – and a new angle for treatment

As common as asthma is, exactly how it starts remains murky. Scientists have now identified a new root cause, and importantly a new angle for treating the disease that can prevent the main symptoms. According to WHO, asthma affects around 262 million people worldwide, but despite its prevalence there’s still much scientists don’t understand about the condition. It’s usually treated as an inflammatory disease – triggers like pollen or dust set off inflammation that narrows the airways and makes it difficult to breathe. Inhaler medications can relieve this by relaxing the airways and calming inflammation. But the new study points to a different root cause, of which inflammation is itself a symptom. When the airway muscles contract – known as bronchoconstriction – the epithelial cells that line the airways are 'squeezed out' and later die. With fewer of these cells acting as a barrier, the chances for future asthma attacks increase. “As cell biologists who watch processes, we could see that the physical constriction of an asthma attack causes widespread destruction of the airway barrier,” said Professor Jody Rosenblatt, lead author of the study. “Without this barrier, asthma sufferers are far more likely to get long-term inflammation, wound healing, and infections that cause more attacks. By understanding this fundamental mechanism, we are now in a better position to prevent all these events.” The team made the discovery in mouse models, and importantly also found a potential way to prevent too much cell extrusion. The chemical compound gadolinium was previously found to block the process, and in the new study the researchers showed that it worked in mice to prevent cell damage and inflammation associated with asthma attacks. “Current therapies do not prevent this destruction – an inhaler such as Albuterol opens the airways, which is critical to breathing but, dishearteningly, we found it does not prevent the damage and the symptoms that follow an attack,” said Rosenblatt. “Fortunately, we found that we can use an inexpensive compound, gadolinium which is frequently used for MRI imaging, to stop the airway damage in mice models as well as the ensuing inflammation and mucus secretion. Preventing this damage could then prevent the build-up of musculature that cause future attacks.” Of course, mice aren’t humans, so there’s no guarantee that these results will necessarily carry across to humans. But the team says that the new study could help lead to new types of asthma therapies that aren’t just about treating symptoms. The research was published in the journal Science.

  • 1 May, 15:21
  • Read more
Нажмите на кнопку ниже, чтобы прослушать текст Powered by GSpeech